Zidovudine, didanosine, and zalcitabine in the treatment of HIV infection: Meta-analyses of the randomised evidence

Lancet

Volumn 353, Issue 9169, 1999, Pages 2014-2025

  Darbyshire, J H ^a   Babiker, A ^a   Collins, R ^a   Duncan, W ^a   Foulkes, M ^a   Hughes, M ^a   Peto, R ^a   Peto, T ^a   Walker, S ^a  

^a MEDICAL RESEARCH COUNCIL   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIRETROVIRUS AGENT; DIDANOSINE; NUCLEOSIDE ANALOG; PROTEINASE INHIBITOR; ZALCITABINE; ZIDOVUDINE;

ACQUIRED IMMUNE DEFICIENCY SYNDROME; ADULT; ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; DISEASE COURSE; FEMALE; FOLLOW UP; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; MAJOR CLINICAL STUDY; MALE; META ANALYSIS; MORTALITY; PRIORITY JOURNAL; PROBABILITY; RANDOMIZED CONTROLLED TRIAL; SURVIVAL;

EID: 0033549284     PISSN: 01406736     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0140-6736(98)12263-8     Document Type: Article

References (41)

1. Fischl M.A., Richman D.D., Grieco M.H.et al. The efficacy of azidothymidine (AZT) in the treatment of patients with AIDS and AIDS-related complex: a double-blind, placebo-controlled trial. N Engl J Med. 317:1987;185-191.
2. Volberding P.A., Graham N.M.H. Initiation of antiretroviral therapy in HIV infection: a review of interstudy consistencies. J Acquir Immune Defic Syndr. 7:1994;S12-23.
3. Dickersin K., Larson K. Establishing and maintaining an international register of RCTs. In: The Cochrane Collaboration Handbook. Oxford: The Cochrane Collaboration, 1995. Available in: The Cochrane Library, Oxford: Update Software, 1996. Updated quarterly.
4. Fischl M.A., Richman D.D., Hansen N.et al. The safety and efficacy of zidovudine (AZT) in the treatment of subjects with mildly symptomatic human immunodeficiency virus type 1 (HIV) infection. Ann Intern Med. 112:1990;727-737.
5. Volberding P.A., Lagakos S.W., Koch M.A.et al. Zidovudine in asymptomatic HIV infection: a controlled trial in persons with fewer than 500 CD4-positive cells per cubic millimeter. N Engl J Med. 322:1990;941-949.
6. Volberding P.A., Lagakos S.W., Grimes J.M.et al. A comparison of immediate with deferred zidovudine therapy for asymptomatic HIV-infected adults with CD4 cell counts of 500 or more per cubic millimeter. N Engl J Med. 333:1995;401-407.
7. Merigan T.C., Amato D.A., Balsley J.et al. Placebo-controlled trial to evaluate zidovudine in treatment of HIV infection in asymptomatic patients with hemophilia. Blood. 78:1991;900-906.
8. Concorde: MRC/ ANRS randomised double-blind controlled trial of immediate and deferred zidovudine in symptom-free HIV infection. Lancet. 343:1994;871-882.
9. Mannucci P.M., Gringeri A., Savidge G.et al. Randomized double-blind, placebo-controlled trial of twice daily zidovudine in asymptomatic haemophiliacs infected with HIV type-1. Br J Haematol. 86:1994;174-179.
10. Mulder J.W., Cooper D.A., Mathiesen L.et al. Zidovudine twice daily in asymptomatic subjects with HIV infection and a high risk of progression to AIDS: a randomised, double-blind placebo-controlled study. AIDS. 8:1994;313-321.
11. Cooper D.A., Gatell J.M., Kroon S.et al. Zidovudine in persons with asymptomatic HIV infection and CD4 cell counts greater than 400 per cubic millimeter. N Engl J Med. 329:1993;297-303.
12. Kinloch-De Loes S., Hirschel B.J., Hoen B.et al. A controlled trial of zidovudine in primary HIV infection. N Engl J Med. 333:1995;408-413.
13. Hamilton J.D., Hartigan P.M., Simberkoff M.S.et al. A controlled trial of early versus late treatment with zidovudine in symptomatic HIV infection. N Engl J Med. 326:1992;437-448.
14. Classification system for human T-lymphotropic virus type III/lymphadenopathy-associated virus infections. Ann Intern Med. 105:1986;234-237.
15. Revision of the CDC surveillance case definition for acquired immunodeficiency syndrome. MMWR Mor Mortal Wkly Rep. 36(suppl 1S):1987;1-15.
16. Fischl M.A., Stanley K., Collier A.C.et al. Combination and monotherapy with zidovudine and zalcitabine in patients with advanced HIV disease. Ann Intern Med. 122:1995;24-32.
17. Hammer S.M., Katzenstein D.A., Hughes M.D.et al. A trial comparing nucleoside monotherapy with combination therapy in HIV-infected adults with CD4 cell counts from 200 to 500 per cubic millimeter. N Engl J Med. 335:1996;1081-1090.
18. Henry W.K., Erice A., Tierney C.et al. A randomized, controlled, double-blind study comparing the survival benefit of four different reverse transcriptase inhibitor therapies (three-drug, two-drug, and alternating drug) for the treatment of advanced AIDS. J Acquir Immune Defic Syndr Hum Retrovirol. 19:1998;339-349.
19. Saravolatz L.D., Winslow D.L., Collins G.et al. Zidovudine alone or in combination with didanosine or zalcitabine in HIV-infected patients with the acquired immunodeficiency syndrome or fewer than 200 CD4 cells per cubic millimeter. N Engl J Med. 335:1996;1099-1106.
20. Delta: a randomised double-blind controlled trial comparing combinations of zidovudine plus didanosine or zalcitabine with zidovudine alone in HIV-infected individuals. Lancet. 348:1996;283-291.
21. Schooley R.T., Ramirez-Ronda C., Lange J.M.A.et al. Virologic and immunologic benefits of initial combination therapy with zidovudine and zalcitabine or didanosine compared with zidovudine monotherapy. J Infect Dis. 173:1996;1354-1366.
22. Englund J.A., Baker C.J., Raskino C.et al. Treatment with zidovudine, didanosine or both as the initial treatment for symptomatic HIV-infected children. N Engl J Med. 336:1997;1704-1712.
23. McKinney R.E. Jr., Johnson G.M., Stanley K.et al. A randomized study of combined zidovudine-lamivudine versus didanosine monotherapy in children with symptomatic therapy-naïve HIV-1 infection. J Pediatr. 133:1998;500-508.
24. Dolin R., Amato D.A., Fischl M.A.et al. Zidovudine compared with didanosine in patients with advanced HIV type 1 infection and little or no previous experience with zidovudine. Arch Intern Med. 155:1995;961-974.
25. Floridia M., Vella S., Seeber A.C.et al. A randomized trial (ISS 902) of didanosine versus zidovudine in previously untreated patients with mildly symptomatic human immunodeficiency virus infection. J Infect Dis. 175:1997;255-264.
26. Kahn J.O., Lagakos S.W., Richman D.D.et al. A controlled trial comparing continued zidovudine with didanosine in human immunodeficiency virus infection. N Engl J Med. 327:1992;581-587.
27. Spruance S.L., Pavia A.T., Peterson D.et al. Didanosine compared with continuation of zidovudine in HIV-infected patients with signs of clinical deterioration while receiving zidovudine: a randomized, double-blind clinical trial. Ann Intern Med. 120:1994;360-368.
28. 3. Ann Intern Med. 123:1995;561-571.
29. Gatell J.M., Gonzalez-Lahoz J., Clotet B.et al. Switching from zidovudine to didanosine in patients with symptomatic HIV infection and disease progression. J Acquir Immune Defic Syndr. 12:1996;249-258.
30. Vella S., Floridia M., Dally L.G.et al. A randomized trial (ISS 901) of switching to didanosine versus continued zidovudine after the diagnosis of AIDS. J Acquir Immune Defic Syndr. 12:1996;462-469.
31. Follansbee S., Drew L., Olson R., et al. The efficacy of zalcitabine (ddC., Hivid) versus zidovudine (ZDV) as monotherapy in ZDV naive patients with advanced HIV disease: a randomized, double-blind, comparative trial (ACTG 114; N3300). In: Program of the 9th International Conference on AIDS. Berlin, June 1993: abstr PO-B26-2113: 487.
32. Fischl M.A., Olson R.M., Follansbee S.E.et al. Zalcitabine compared with zidovudine in patients with advanced HIV-1 infection who received previous zidovudine therapy. Ann Intern Med. 118:1993;762-769.
33. Abrams D.I., Goldman A.I., Launer C.et al. A comparative trial of didanosine or zalcitabine after treatment with zidovudine in patients with human immunodeficiency virus infection. N Engl J Med. 330:1994;657-663.
34. Treatment of early breast cancer: worldwide evidence 1985-1990. 1990;Oxford University Press, Oxford.
35. Montaner J.S.G., Hogg R., Raboud J., Harrigan R., O'Shaughnessy M. Antiretroviral treatment in 1998. Lancet. 352:1998;1919-1922.
36. Ioannidis J.P.A., Cappelleri J.C., Lau J.et al. Early or deferred zidovudine therapy in HIV-infected patients without an AIDS-defining illness. Ann Intern Med. 122:1995;856-866.
37. Fischl M.A., Richman D.D., Causey D.M.et al. Prolonged zidovudine therapy in patients with AIDS and advanced AIDS-related complex. JAMA. 262:1989;2405-2410.
38. Raboud J.M., Montaner J.S.G., Rae S.et al. Meta-analysis of five randomized controlled trials comparing continuation of zidovudine versus switching to didanosine in HIV-infected individuals. Antivir Ther. 2:1997;237-247.
39. Randomised trial of addition of lamivudine or lamivudine plus loviride to zidovudine-containing regimens for patients with HIV-1 infection: the CAESAR trial. Lancet. 349:1997;1413-1421.
40. Staszewski S., Hill A.M., Bartlett J.et al. Reductions in HIV-1 disease progression for zidovudine/lamivudine relative to control treatments: a meta-analysis of controlled trials. AIDS. 11:1997;477-483.
41. Hammer S.M., Squires K.E., Hughes M.D.et al. A controlled trial of two nucleoside analogues plus indinavir in persons with human immunodeficiency virus infection and CD4 cell counts of 200 per cubic millimeter or less. N Engl J Med. 337:1997;725-733.